Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Amado Rafael, President and Head of Global Oncology Research and Development at Zai Lab Ltd (NASDAQ:ZLAB), recently sold 3,000 American Depositary Shares (ADS) of the company. The shares were sold at a price of $38.41 each, amounting to a total transaction value of $115,229. Following this sale, Rafael retains ownership of 30,834 ADS. The transaction comes as ZLAB trades near its 52-week high of $39.61, having delivered an impressive 108% return over the past year. InvestingPro analysis reveals strong momentum, with the stock up nearly 80% in the last six months.
Each ADS represents ten ordinary shares of Zai Lab, a pharmaceutical company based in Shanghai. The transaction was executed under a Rule 10b5-1 trading plan, which Rafael adopted on November 22, 2024. According to InvestingPro, analysts maintain a bullish outlook on ZLAB, with 12 additional exclusive ProTips available to subscribers, offering deeper insights into the company’s financial health and growth prospects.
In other recent news, Zai Lab has been the focus of analyst attention with updates from both Scotiabank (TSX:BNS) and BofA Securities. Scotiabank analyst Louise Chen initiated coverage on Zai Lab with a Sector Outperform rating and set a one-year price target of $55. Chen highlighted Zai Lab’s potential to become a significant global pharmaceutical player, noting the company’s strong execution and promising product lineup. Chen also projected that Zai Lab could become cash flow positive by the fourth quarter of 2025, which could reduce its risk profile.
Meanwhile, BofA Securities downgraded Zai Lab from Buy to Neutral but raised the price target from $29.00 to $36.10. The firm maintained its revenue estimates for 2025-26 but increased its forecast by over 5% starting in 2027. BofA’s analysis pointed to a tempered outlook due to the soft performance of certain products but acknowledged the promising sales ramp-up of others and progress in the pipeline. The analysts also revised key financial metrics, such as the weighted average cost of capital, to reflect the updated outlook. These developments indicate that Zai Lab is navigating a complex landscape, with investors closely watching how these changes might influence the company’s future trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.